FIELD: medicine.
SUBSTANCE: invention relates to novel peptide compounds, which possess ability to inhibit protease of hepatitis C virus (HCV), their pharmaceutical compositions and application of compounds for obtaining medication for diseases associated with HCV.
EFFECT: improvement of compound properties.
48 cl, 6 tbl, 65 ex
Title | Year | Author | Number |
---|---|---|---|
3,4-DISUBSTITUTED CYCLOBUTENE-1,2-DIONES AS LIGANDS OF CXC-CHEMOKINE RECEPTOR | 2002 |
|
RU2344123C9 |
ANTIVIRAL COMPOUNDS | 2009 |
|
RU2505540C2 |
HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | 2004 |
|
RU2405774C9 |
COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
ANTIVIRAL COMPOUNDS | 2009 |
|
RU2505539C2 |
NOVEL PYRAZOLOPYRIMIDINES AS INHIBITORS OF CYCLIN-DEPENDANT KINASE | 2003 |
|
RU2380369C9 |
OXOAZEPANYLACETAMIDE AND OXOAZEPANYLPHENOXYACETAMIDE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND METHOD FOR INHIBITING HEPATITIS TYPE C VIRUS (HCV) REPLICATION | 2006 |
|
RU2415132C2 |
ANTAGONISTS OF THROMBIN RECEPTOR | 2005 |
|
RU2408594C2 |
BENZOTHIEPINES, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, METHOD OF PROPHYLAXIS AND TREATMENT OF HYPERLIPIDEMIC STATE | 1997 |
|
RU2202549C2 |
POLYCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION POSSESSING PROPERTY OF H RECEPTOR ANTAGONIST AND METHOD FOR TREATMENT BY ITS USING | 2001 |
|
RU2301231C2 |
Authors
Dates
2010-11-20—Published
2003-01-16—Filed